Sufferers so that they may choose to fire away at Frenchmen with the same joy that Americans fire away at prison escapes.
Even an Italian see pubmed.org RISTORI + Bcg knows that the French are killing Americans with expensive dangerous drugs when simple safe and inexpensive Bcg will enable those afflicted with Bcg to shoot accurately at any target that they so desire. Mass general the assignee of patents by Denise l faustman see eg faustmanlab.org pubmed.org faustman and uspto.gov faustman inventor search fails to treat effectively treat multiple sclerosis because mass general does not care about improving human life.
Take the multiple sclerosis kalisnikovchallenge.
Shoot Bcg and test your automatic weapons accuracy before and after so doing
Ready aim kill, shoot Bcg !
Think of all the pissed off Americans who are being killed and or impaired needlessly by mass general and sanofil.
If Obama valued human life he would see that Bcg is freely available in the us and that sanofil's Dope and it's american conspirators were exiled to Syria,
Nov 9 A new lawsuit accuses Sanofi SA of stalling development of its multiple sclerosis drug Lemtrada to avoid paying out at least $708 million to rights holders under its 2011 agreement to acquire Genzyme Corp.
The lawsuit, filed on Monday in Manhattan federal court by American Stock Transfer & Trust Co LLC, a trustee for the rights holders, seeks at least $236.1 million in damages.
Genzyme was in the process of developing Lemtrada when Sanofi bought it. Under the merger agreement, Sanofi issued Genzyme shareholders tradable certificates entitling them to payments if Lemtrada won approval from the U.S. Food and Drug Administration by March 31, 2014, and further payments if it met certain sales benchmarks after that.
Sanofi promised it would make "diligent efforts" to meet those goals, according to the complaint. Instead, the trustee alleges, it deliberately took a "slow path" to bring Lemtrada to market.
The lawsuit claims Sanofi deliberately ignored the FDA's concerns about the designs of its clinical trials, leading the agency to deny the company's first application for approval.
The trustee further claims that even after Lemtrada was finally approved in November 2014, Sanofi skimped on marketing it, while actively promoting a different multiple sclerosis drug, Aubagio. As a result, the lawsuit says, Lemtrada has failed to meet any of the sales benchmarks.
The drug is expected to lose patent protection in September 2017, according to the lawsuit, further limiting its prospects.
Sanofi said in a statement that it was aware of the lawsuit but did not comment on pending litigation.
The case is American Stock Transfer & Trust Company LLC v. Sanofi, U.S. District Court, Southern District of New York, No. 1:15-cv-08725. (Reporting by Brendan Pierson in New York; Editing by Matthew Lewis)
No comments:
Post a Comment